Cargando…

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort

BACKGROUND: Activities of daily living (ADL) are an essential part of the diagnostic criteria for Alzheimer’s disease (AD). A decline in ADL affects independent living and has a strong negative impact on caregiver burden. Functional response to cholinesterase inhibitor (ChEI) treatment and factors t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wattmo, Carina, Wallin, Åsa K, Minthon, Lennart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534216/
https://www.ncbi.nlm.nih.gov/pubmed/23126532
http://dx.doi.org/10.1186/1471-2377-12-134
_version_ 1782475293718478848
author Wattmo, Carina
Wallin, Åsa K
Minthon, Lennart
author_facet Wattmo, Carina
Wallin, Åsa K
Minthon, Lennart
author_sort Wattmo, Carina
collection PubMed
description BACKGROUND: Activities of daily living (ADL) are an essential part of the diagnostic criteria for Alzheimer’s disease (AD). A decline in ADL affects independent living and has a strong negative impact on caregiver burden. Functional response to cholinesterase inhibitor (ChEI) treatment and factors that might influence this response in naturalistic AD patients need investigating. The aim of this study was to identify the socio-demographic and clinical factors that affect the functional response after 6 months of ChEI therapy. METHODS: This prospective, non-randomised, multicentre study in a routine clinical setting included 784 AD patients treated with donepezil, rivastigmine or galantamine. At baseline and after 6 months of treatment, patients were assessed using several rating scales, including the Instrumental Activities of Daily Living (IADL) scale, Physical Self-Maintenance Scale (PSMS) and Mini-Mental State Examination (MMSE). Demographic and clinical characteristics were investigated at baseline. The functional response and the relationships of potential predictors were analysed using general linear models. RESULTS: After 6 months of ChEI treatment, 49% and 74% of patients showed improvement/no change in IADL and in PSMS score, respectively. The improved/unchanged patients exhibited better cognitive status at baseline; regarding improved/unchanged PSMS, patients were younger and used fewer anti-depressants. A more positive functional response to ChEI was observed in younger individuals or among those having the interaction effect of better preserved cognition and lower ADL ability. Patients with fewer concomitant medications or those using NSAIDs/acetylsalicylic acid showed a better PSMS response. CONCLUSIONS: Critical characteristics that may influence the functional response to ChEI in AD were identified. Some predictors differed from those previously shown to affect cognitive response, e.g., lower cognitive ability and older age predicted better cognitive but worse functional response.
format Online
Article
Text
id pubmed-3534216
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35342162013-01-07 Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort Wattmo, Carina Wallin, Åsa K Minthon, Lennart BMC Neurol Research Article BACKGROUND: Activities of daily living (ADL) are an essential part of the diagnostic criteria for Alzheimer’s disease (AD). A decline in ADL affects independent living and has a strong negative impact on caregiver burden. Functional response to cholinesterase inhibitor (ChEI) treatment and factors that might influence this response in naturalistic AD patients need investigating. The aim of this study was to identify the socio-demographic and clinical factors that affect the functional response after 6 months of ChEI therapy. METHODS: This prospective, non-randomised, multicentre study in a routine clinical setting included 784 AD patients treated with donepezil, rivastigmine or galantamine. At baseline and after 6 months of treatment, patients were assessed using several rating scales, including the Instrumental Activities of Daily Living (IADL) scale, Physical Self-Maintenance Scale (PSMS) and Mini-Mental State Examination (MMSE). Demographic and clinical characteristics were investigated at baseline. The functional response and the relationships of potential predictors were analysed using general linear models. RESULTS: After 6 months of ChEI treatment, 49% and 74% of patients showed improvement/no change in IADL and in PSMS score, respectively. The improved/unchanged patients exhibited better cognitive status at baseline; regarding improved/unchanged PSMS, patients were younger and used fewer anti-depressants. A more positive functional response to ChEI was observed in younger individuals or among those having the interaction effect of better preserved cognition and lower ADL ability. Patients with fewer concomitant medications or those using NSAIDs/acetylsalicylic acid showed a better PSMS response. CONCLUSIONS: Critical characteristics that may influence the functional response to ChEI in AD were identified. Some predictors differed from those previously shown to affect cognitive response, e.g., lower cognitive ability and older age predicted better cognitive but worse functional response. BioMed Central 2012-11-05 /pmc/articles/PMC3534216/ /pubmed/23126532 http://dx.doi.org/10.1186/1471-2377-12-134 Text en Copyright ©2012 Wattmo et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wattmo, Carina
Wallin, Åsa K
Minthon, Lennart
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
title Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
title_full Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
title_fullStr Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
title_full_unstemmed Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
title_short Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
title_sort functional response to cholinesterase inhibitor therapy in a naturalistic alzheimer’s disease cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534216/
https://www.ncbi.nlm.nih.gov/pubmed/23126532
http://dx.doi.org/10.1186/1471-2377-12-134
work_keys_str_mv AT wattmocarina functionalresponsetocholinesteraseinhibitortherapyinanaturalisticalzheimersdiseasecohort
AT wallinasak functionalresponsetocholinesteraseinhibitortherapyinanaturalisticalzheimersdiseasecohort
AT minthonlennart functionalresponsetocholinesteraseinhibitortherapyinanaturalisticalzheimersdiseasecohort